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ABSTRACT 
Objective: A standard causality assessment tool of an adverse drug reaction (ADR) is essential to compute the risk-benefit assessment of the 
medication taken by the patient and categorize its relationship likelihood. It should be reproducible and should not differ with the background and 
experience of the evaluator. Though there are a large number of causality assessment tools, none is unanimously accepted worldwide. So, this study 
was done to assess the agreement between three frequently used methods of causality assessment, the World Health Organisation-Uppsala 
Monitoring Centre (WHO-UMC) system, the Naranjo’s algorithm, and the Liverpool algorithm. 
Methods: 172 ADR forms from the pharmacovigilance unit were randomly selected for the study. Causality assessment was done using three 
different methods, the WHO-UMC system, Naranjo’s algorithm, and the Liver pool algorithm. Cohen’s Kappa statistics was applied to look for 
agreement between the causality assessment methods. 
Results: The agreement between the WHO-UMC criteria and Naranjo’s algorithm was the highest (136), with a Kappa value of 0.511, suggesting a 
moderate level of agreement. A maximum number of disagreements were noted between the WHO-UMC system and the Liverpool algorithm 
method (110). 
Conclusion: A moderate agreement exists between the WHO-UMC system and the Naranjo algorithm. There is poor agreement between the 
Liverpool algorithm and the other two scales. Therefore, it is recommended that both the WHO-UMC system and the Naranjo algorithm be used for 
causality assessment of ADRs.  
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INTRODUCTION 
Causality assessment is needed to prove the relationship between 
the drug used and the adverse event following its use [1]. Adverse 
drug reactions (ADR) are recognized as the seventh recurrent cause 
of death [2] and it is also known that one in seven hospitalized 
patients develops an ADR [3]. The majority of the ADRs, though mild 
to moderate, need hospitalization and immediate treatment [4]. The 
various measurable risk factors for an ADR include polypharmacy, 
co-morbidities, length of stay at the hospital, age, previous history of 
ADRs and gender of the patient [5]. Therefore, a standard causality 
assessment tool is essential to compute the risk-benefit assessment 
of the medication taken and categorize the relationship likelihood. It 
should be reproducible in all circumstances and should not differ 
with the background and experience of the evaluator [6]. Methods of 
causality assessment can be broadly divided into expert judgment or 
global introspection, Bayesian methods and algorithms. Though 
there are a large number of causality assessment tools, none is 
unanimously accepted throughout the world [6]. Hence it is very 
essential to explore and analyze these methods to what degree they 
agree or differ.  
The World Health Organisation-Uppsala monitoring center (WHO-
UMC) causality assessment system was first introduced in 1994. It is 
a convenient tool for assessing individual case reports. But being a 
non-probabilistic method, it creates extensive unpredictability in 
evaluation. The Pharmacovigilance Program of India (PvPI) 
recommends the use of WHO-UMC criteria because of its simplicity 
and fast assessment properties [7]. Naranjo’s algorithm is preferred 
by many clinicians because it has a lower rate of inter-rater 
disagreement and uncertainty in ADR evaluation [8]. But, the main 
concern of Naranjo’s scale is its poor application in the pediatric age 
group and inclusion of queries regarding re-challenge and de-
challenge, which makes it unethical and difficult. The exclusion of 
these queries will make the assessment output more limited to the 
maximum number of ADRs, turning to have a “possible” association 
[9]. Another causality assessment method which is more user 
friendly, devoid of uncertainty, and more suitable in children as well 
as in adults is the Liverpool algorithm. It is based on a robust binary 
decision where responses are redirected to precise queries rather 
than scores. This method gives more ADRs as “definite” than using 
Naranjo’s [10]. 
Though these three causality assessment tools are widely used, 
there is not enough exploration done to compare these tools. So, this 
study was done to assess the agreement between the three different 
methods of causality assessment scales, the WHO-UMC system, 
Naranjo’s algorithm, and Liverpool algorithm. 
MATERIALS AND METHODS 
The ADR CDSCO forms were obtained from the pharmacovigilance 
unit of the hospital. 172 ADR forms were randomly selected for the 
study. Causality assessment was done using three assessment 
criteria, the WHO-UMC system, Naranjo’s algorithm and the Liver 
pool algorithm. Cohen’s Kappa statistics was applied to look for 
agreement across the three causality assessment methods.  
RESULTS 
Among the 172 ADR forms collected, the mean age of the patients 
was found to be 48, with the minimum being 2 y and the maximum 
being 94. More number of females (108) reported with ADRs than 
males (64). 45% of ADRs were labeled as serious according to WHO 
criteria. The maximum number of ADRs was assessed to be 
“probable” by both the WHO-UMC system (123) and Naranjo’s (126). 
On the other hand, the Liverpool causality algorithm had more 
number of ADRs identified as “possible” (113). Overall agreement 
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between the WHO-UMC system and Naranjo”s algorithm was the 
highest (136) with a Kappa value of 0.511, suggesting a moderate 
level of agreement. A maximum number of disagreements was noted 
between the WHO-UMC system and Liverpool algorithm methods 
(110).
 
Table 1: Category-wise distribution of ADRs using WHO-UMC system, Naranjo’s and Liverpool casualty assessment tools 
WHO-UMC system No of ADRs (%) Naranjo’s No of ADRs (%) Liverpool algorithm No of ADRs (%) 
Certain  13(7.6) Definite  9(5.2) Definite  8(5.8) 
Probable  123(71.5) Probable  126(73.3) Probable  49(28.5) 
Possible  35(20.3) Possible 37(21.5) Possible 113(65.7) 
Unlikely  1(0.6) Doubtful 0 Unlikely  0 
Unclassified  0     
Unclassifiable 0     
 
Table 2: Comparison of agreement between the three methods of causality assessment scales 
 Certain/definite Probable  Possible  Unlikely Total   Kappa value (κ) 
WHO UMC and Liverpool  10 32 21 0 63 .037 
WHO-UMC and Naranjo 9 107 20 0 136 .511 
Naranjo and Liverpool  9 39 27 0 75 .128 
Kappa value (κ) was calculated using Cohen’s kappa statistics 
 
Table 3: Number of disagreements across the three methods of causality assessment 
Causality assessment method Total disagreements 
WHO UMC and Liverpool  110 
WHO-UMC and Naranjo 36 
Naranjo and Liverpool  97 
 
DISCUSSION 
The majority of the ADR’s found by the WHO-UMC system is 
“Probable”(71.5%) category followed by Possible(20.3%), 
Certain(7.6%) and Unlikely(0.6%). A similar pattern of causality is 
seen with the Naranjo’s algorithm having 73.3% of ADRs in the 
“Probable” order, followed by Possible (21.5%) and the least in 
(5.2%) Certain. This parallelism in both the scales is in agreement 
with the earlier studies done by Tejas. A. Acharya et al. [11], Roy et 
al. [12] and Nitti Mittal et al. [13], where the probable category was 
the highest in both the tools. In contrast to this, many studies show 
that the “Possible” criteria to be prominent, as seen in Behelkar MN 
et al. [14] and Lei et al. [15]. This deviation can be due to the types of 
ADRs encountered in different hospital setups and also the 
subjectivity involved in analyzing the WHO-UMC system. Liverpool 
causality assessment results in this study were at variance from the 
other two tools used, with the highest number of ADRs falling in the 
“Possible” (113) category followed by Probable with 49 ADRs and 8 
ADRs with Certain category. Though the maximum number of 
“Possible” aligns with a study done by Helene Theophile et al. [16], 
the same study had a high level of agreement between Naranjo’s and 
Liverpool’s, which is not evident in the current study. 
Cohen’s kappa showed a moderate agreement between Naranjo’s 
and WHO_UMC system (.511). There is poor agreement between the 
other Causality tools. The moderate level agreement which was 
implicated in this study aligns with the studies done by Thaker SJ 
(kappa=0.69) [17] and Tejas. A. Acharya (kappa=0.60) [11]. But 
lower kappa values were found in other studies like Rehan et al. 
(kappa=0.214) [18], Belheker et al. [14] (kappa=0.145) and Rana et 
al. (kappa=0.014) [19]. The reason for this variability can be due to 
the high subjectivity, clinical knowledge, and experience of different 
evaluators. Other factors like drug re-challenge in the WHO-UMC 
system and subjectivity questions in Naranjo’s algorithm can be 
contributing to these different outcomes. 
Assuming that a drug is the cause of an ADR, the decision is made 
whether to continue or stop the drug, which is a big drawback and 
can sometimes even endanger the patient’s treatment. In every 
patient, the outcome of a causality assessment algorithm can never 
replace a good clinical diagnosis. The clinicians must understand 
how the scales perform at assessing ADRs using to interpret a 
clinical diagnosis. Keeping in mind these practical issues, some areas 
need to be revised in the causality assessment methods. 
However, our study is limited by the fact that only three ADR 
causality assessment scales were included and the number of ADRs 
used for analysis was also comparatively smaller. Further studies 
are required to establish an agreement between the different 
causality assessment methods. 
CONCLUSION 
We conclude that moderate agreement exists between the WHO-
UMC causality system and the Naranjo algorithm. There is poor 
agreement between the Liverpool algorithm and the other two 
scales. Therefore, it is recommended that both the WHO-UMC 
causality system and the Naranjo algorithm be used for causality 
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